Your browser doesn't support javascript.
loading
Patients with coronary artery disease after acute myocardial infarction: effects of continuous enrollment in a structured Disease Management Program on adherence to guideline-recommended medication, health care expenditures, and survival.
Kirsch, Florian; Becker, Christian; Schramm, Anja; Maier, Werner; Leidl, Reiner.
Afiliação
  • Kirsch F; Institute of Health Economics and Health Care Management, Helmholtz Zentrum München, Neuherberg, Germany. florian.kirsch@helmholtz-muenchen.de.
  • Becker C; Munich School of Management and Munich Center of Health Sciences, Ludwig-Maximilians-Universität, Munich, Germany. florian.kirsch@helmholtz-muenchen.de.
  • Schramm A; Institute of Health Economics and Health Care Management, Helmholtz Zentrum München, Neuherberg, Germany.
  • Maier W; AOK Bayern, Service Center of Health Care Management, Regensburg, Germany.
  • Leidl R; Institute of Health Economics and Health Care Management, Helmholtz Zentrum München, Neuherberg, Germany.
Eur J Health Econ ; 21(4): 607-619, 2020 Jun.
Article em En | MEDLINE | ID: mdl-32006188
ABSTRACT

OBJECTIVE:

Acute myocardial infarction (AMI) carries increased risk of mortality and excess costs. Disease Management Programs (DMPs) providing guideline-recommended care for chronic diseases seem an intuitively appealing way to enhance health outcomes for patients with chronic conditions such as AMI. The aim of the study is to compare adherence to guideline-recommended medication, health care expenditures and survival of patients enrolled and not enrolled in the German DMP for coronary artery disease (CAD) after an AMI from the perspective of a third-party payer over a follow-up period of 3 years.

METHODS:

The study is based on routinely collected data from a regional statutory health insurance fund (n = 15,360). A propensity score matching with caliper method was conducted. Afterwards guideline-recommended medication, health care expenditures, and survival between patients enrolled and not enrolled in the DMP were compared with generalized linear and Cox proportional hazard models.

RESULTS:

The propensity score matching resulted in 3870 pairs of AMI patients previously and continuously enrolled and not enrolled in the DMP. In the 3-year follow-up period the proportion of days covered rates for ACE-inhibitors (60.95% vs. 58.92%), anti-platelet agents (74.20% vs. 70.66%), statins (54.18% vs. 52.13%), and ß-blockers (61.95% vs. 52.64%) were higher in the DMP group. Besides that, DMP participants induced lower health care expenditures per day (€58.24 vs. €72.72) and had a significantly lower risk of death (HR 0.757).

CONCLUSION:

Previous and continuous enrollment in the DMP CAD for patients after AMI is a promising strategy as it enhances guideline-recommended medication, reduces health care expenditures and the risk of death.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Gastos em Saúde / Gerenciamento Clínico / Adesão à Medicação / Infarto do Miocárdio Tipo de estudo: Guideline / Health_economic_evaluation / Prognostic_studies Limite: Female / Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Gastos em Saúde / Gerenciamento Clínico / Adesão à Medicação / Infarto do Miocárdio Tipo de estudo: Guideline / Health_economic_evaluation / Prognostic_studies Limite: Female / Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article